Results 121 to 130 of about 63,889 (276)

Comparison of efficacy of the tumour necrosis factor alpha blocking agents Etanercept and Infliximab in patients with active rheumatoid arthritis

, 2005
Background: Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly improved the outcomes in patients with rheumatoid arthritis (RA).
SANGARI D, DE FILIPPIS LG, MICALI G, ROMEO C, SCIBILIA G, BAGNATO, Gianfilippo, CALIRI A, LO GULLO R., BARTOLONE S   +8 more
core   +2 more sources

Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results

, 2018
Yuji Nozaki, Yasuaki Nagare, Chisato Ashida, Daisuke Tomita, Akinori Okada, Asuka Inoue, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura Department of Hematology and Rheumatology, Kindai University School of Medicine, Osaka, Japan Purpose: We ...
Kinoshita K, Ashida C, Matsumura I, Inoue A, Nozaki Y, Funauchi M, Okada A, Tomita D, Nagare Y   +8 more
core  

Microbiota Transplantation Effectively Treats Immune Checkpoint Inhibitor‐Associated Colitis: A Multi‐Center, Retrospective Case Series

Microbiota Medicine Research, EarlyView.
ABSTRACT Background Immune‐mediated colitis is an adverse effect of therapy with immune checkpoint inhibitors (ICIs). This study aims to evaluate the efficacy and safety of washed microbiota transplantation (WMT) in patients with ICI‐associated colitis.
Mengyu Huang, Yaping Liu, Hong Lu, Weihong Wang, Huiying Gao, Junlan Qiu, Yan Jin, Qian Ren   +7 more
wiley   +1 more source

The impact of malnutrition on clinical outcomes in patients with perianal fistulizing Crohn's disease undergoing seton placement: A retrospective study

Nutrition in Clinical Practice, EarlyView.
Abstract Background Perianal involvement occurs in up to 50% of patients with Crohn's disease (CD). Despite combined management, 10%–20% require fecal diversion or proctectomy. Nutritional status may influence prognosis, but its role in fistulizing perianal disease is unclear.
Bruno Augusto Alves Martins, Oswaldo de Moraes Filho, Tuane Colles, Clíslian Silva, Gabriela de Oliveira Lemos, Dannilo Brito Silveira, Heitor Siqueira Ribeiro, João Batista de Sousa   +7 more
wiley   +1 more source

Infection risk in rheumatoid arthritis patients treated with biologic and targeted therapies

Rheumatology &Autoimmunity, EarlyView.
In this context, infections associated with each biologic and targeted drug are summarized to inform the stratification of RA patients, including the characteristics of the susceptible patients and their concomitant therapy. We aim to provide a benefit‐risk analysis for clinical decision, and vital indications for the prevention of highly correlated ...
Lujing Wang, Jieshi Lin, Jie Qian
wiley   +1 more source

Assessment of Major Adverse Cardiovascular Event Across Diverse Racial Groups of Psoriasis Patients on Biologic Therapy: A Retrospective Cohort Study

The Journal of Dermatology, EarlyView.
ABSTRACT Psoriasis is associated with an increased risk of major adverse cardiovascular events (MACE), and biologic therapy may reduce this risk by targeting systemic inflammation. However, limited data exist on whether long term MACE risk differs by biologic class or across racial groups. We conducted a retrospective cohort study to assess the risk of
Chunghwan Ro, Ana Ormaza Vera, Waleed Adawi, Clinton W. Enos   +3 more
wiley   +1 more source

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada, Yoshiko Maeda, Miyuki Hasegawa, Motonobu Sakaguchi, Takamasa Hashimoto, Teruko Narusawa, Nobuyoshi Takabayashi, Tomoko Takahashi, Taisuke Kondo, Shingo Kuroda   +9 more
wiley   +1 more source

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source

Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn's disease

, 2012
Chureen T Carter,1 Heidi C Waters,1 Daniel B Smith21Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, USA; 2Statistics, IMS Health, Watertown, MA, USABackground: To assess the impact of a continuous measure of ...
Carter CT, Smith DB, Waters HC
core  

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

Allergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud, Lene Heise Garvey, Elizabeth Phillips, Michael Ardern‐Jones, Sevim Bavbek, Patrizia Bonadonna, Jean‐Christoph Caubet, Ana‐Maria Copaescu, Valentina Gueli, Jose Julio Laguna, Ricardo Madrigal‐Burgaleta, Francesca Mori, Vito Sabato, Maria J Torres, Knut Brockow   +14 more
wiley   +1 more source